Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 18/20 | 1.00 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4298020 | 0.94 | DGAT1 (0.88) | DGAT1EPHX2 | |
| SCHEMBL4300242 | 0.94 | DGAT1 (0.88) | DGAT1EPHX2 | |
| SCHEMBL4291815 | 0.92 | DGAT1 (0.85) | DGAT1EPHX2 | |
| SCHEMBL4297984 | 0.92 | DGAT1 (1.00) | DGAT1 | |
| SCHEMBL4301695 | 0.91 | DGAT1 (0.83) | DGAT1EPHX2 | |
| SCHEMBL4294103 | 0.91 | DGAT1 (0.84) | DGAT1EPHX2 | |
| SCHEMBL4289602 | 0.90 | DGAT1 (0.86) | DGAT1EPHX2 | |
| SCHEMBL4300131 | 0.90 | DGAT1 (0.81) | DGAT1EPHX2CYP2C9CYP2C19CYP2J2 | |
| SCHEMBL4299795 | 0.90 | DGAT1 (0.81) | DGAT1 | |
| SCHEMBL4289624 | 0.90 | DGAT1 (0.81) | DGAT1EPHX2CYP2C9CYP2C19CYP2J2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286791-A1 | Amide Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-19 | — | — | US | claimed |
| EP-2044055-A2 | AMIDE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2009-04-08 | — | — | EP | claimed |
| WO-2008011131-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | claimed |
| US-20090286791-A1 | Amide Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286791-A1 | Amide Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286791-A1 | Amide Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2044055-A2 | AMIDE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008011131-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286791-A1 | Amide Compounds | DLAT, DGAT2, DGAT1 | DGAT1 3/4885EPHX2 1912/4885CYP2C9 2594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.